Clinical Trial Update: Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results update on Abraxane combined with an anti-PD1/PDL1 inhibitor in advanced urothelial carcinoma; the study is completed and results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• anti-PD1/PDL1 antibody (PD-1/PD-L1 inhibitor)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Urothelial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-01-16